-+ 0.00%
-+ 0.00%
-+ 0.00%

OPKO Health Expands Partnership With Entera Bio To Advance First-in-Class Oral Long Acting PTH Tablet

Benzinga·02/04/2026 13:05:59
Listen to the news

This is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilities

The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026

Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; oral OXM to enter clinic thereafter

Industry veteran Steve Rubin joins Entera's board